Allos Therapeutics to Present at the RBC Capital Markets 2008 Healthcare Conference.WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company's senior management will participate in a panel presentation, "Waging a Battle Against Cancer," at the RBC Capital Markets RBC Capital Markets is the corporate and investment banking division of Royal Bank of Canada ("RBC"). Broker dealers Depending on the jurisdiction, the division uses different broker dealer subsidiaries of RBC:
The panel presentation will take place at 8:00 a.m. (Eastern) on Tuesday, December 11, 2008. There will be a live webcast of the presentation, which will be accessible through a link posted on the Allos website home page and investor relations Investor relations The process by which the corporation communicates with its investors. section. The webcast will be available for replay on Allos' website through December 26, 2008. About Allos Therapeutics, Inc. Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX PDX Product Data Exchange (file name extension; XML technology) PDX Paradox Files (file name extension) PDX Product Definition Exchange PDX Phone Data Exchange (Proxon) ), is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma T-cell lymphoma A malignant proliferation of T cells arising in the skin, diagnosed by detecting rearrangement of the T-cell receptor's β chain; TCLs are often 'driven' by EBV and other viral infections; 90% of all Pts with TCL have extracutaneous involvement . The Company reported top line results from PROPEL in December 2008. Following review of the final results of the trial, the Company intends to submit a New Drug Application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for pralatrexate for the treatment of patients with relapsed or refractory PTCL PTCL Pakistan Telecommunication Company Limited PTCL Peripheral T Cell Lymphoma PTCL Physical and Theoretical Chemistry Laboratory PTCL Pakistan Tobacco Company Limited in the first half of 2009. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment (SPA) process. The Company is also investigating pralatrexate in patients with non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. , bladder cancer and a range of lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent currently being evaluated in a Phase 1 trial in patients with advanced solid tumors or non-Hodgkin's lymphoma (NHL NHL Non-Hodgkin's lymphoma, see there ). The Company currently retains exclusive worldwide rights to pralatrexate and RH1 for all indications. For additional information, please visit the Company's website at www.allos.com. Safe Harbor Statement The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Additional information concerning these forward-looking statements and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. All forward-looking statements are based on information currently available to the Company on the date thereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion